fda statement bpc-157 not approved for human use compounding vs. TB-500: What Patients Should Know FDA Committee Votes to Ease

Although we expected the largest microbiome differences to occur in the lean control group relative to the obese control group, we found that the diet-switched groups exhibited a greater number of differences from the control groups than the control groups did from one another

DOI:10.1096/fasebj.2019.33.1\_supplement.822.4

Nutrition is not an afterthought in peptide therapy

A calibration for niclosamide concentration (y) versus UV absorbance at 333nm (x) was first obtained on a Thermo Scientific Nanodrop 1000 UV/Vis Spectrophotometer over the range 25uM-300uM niclosamide, providing a linear fit of y = 0.0014x - 0.0006

The neurological symptoms can be particularly concerning